New drug combo tested for Tough-to-Treat stomach cancer
NCT ID NCT05419362
Summary
This study tested whether adding a new oral drug called GEN-001 to an existing immunotherapy (avelumab) could help control advanced stomach or gastroesophageal junction cancer. It was for patients whose cancer had worsened after at least two prior standard treatments and who had not received certain immunotherapies before. The main goal was to see if the combination could shrink tumors and was safe for participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Ajou University Hospital
Gyeonggi-do, South Korea
-
Asan Medical Center
Seoul, South Korea
-
Samsung Medical Center
Seoul, South Korea
-
Seoul National University Bundang Hospital
Gyeonggi-do, South Korea
-
Yonsei University Health System, Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.